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ABSTRACT 
The recent literature with some special interest on the principal mechanism of floatation to obtain gastric retention is the main purpose of 
writing this review on floating drug delivery systems (FDDS). The recent developments in floating drug delivery systems are containing the 
physiological and formulation variables impacting on gastric retention time, approaches to formulating of single-unit and multiple-unit floating 
systems, and their classification and formulation aspects are discussed in detail. This review also summarizes evaluation parameters and 
application of floating drug delivery systems. These systems are useful to several problems introduced during the formulations of a 
pharmaceutical dosage form. 
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INTRODUCTION 
The solid oral dosage forms such as capsules, tablets gives 
specific drug concentration in Systemic blood circulation 
without getting any control over drug delivery system and 
also cause major fluctuations in plasma drug 
concentrations.[1] There are so  many attempts have been 
performed to develop prolonged(sustained) release 
preparations with extended clinical effects and reduced 
frequency of dose.  A problem continuously encountered 
with conventional sustained release dosage forms is the 
residence time in stomach is unable to increase and there is 
no control over drug delivery of drug which leads to 
fluctuations in plasma drug concentration level. The most 
convenient and preferred means of any drug delivery to the 
systematic circulation is the oral Administration. To achieve 
improved therapeutic advantages the oral controlled release 
drug delivery system have recently been of increasing 
interest in pharmaceutical field, such as ease of 
administration of doses, patient compliance towards the 
product and flexibility in formulation of drug.[2]  Those 
drugs are eliminated quickly from the systemic circulation 
who are easily absorbed from gastrointestinal tract (GIT) 
and have short half-life. To achieve suitable therapeutic 
activity in body these drugs is required frequent dosing. The 
development of sustained-controlled release oral 
formulations is to avoid this limitation and it is an attempt to 
release the drug slowly into the gastrointestinal tract and 
maintain the therapeutic drug concentration in the blood 
circulation for a long period of time. For to get maximum 
gastric retention of solid dosage forms is followed by the 
mechanisms of muco-adhesion, sedimentation, flotation, 
modified shape systems, expansion, or by the simultaneous 
administration of pharmacological agents followed by gastric 
emptying. The classification of floating drug delivery systems 
(FDDS) has been described in detail on the basis of these 
approaches. [1] To get  the efficiency and application of such 
systems the in vivo/in vitro evaluation of FDDS has also been 
discussed by the researchers. With bioavailability problems 
several recent examples have also been reported showing 
the efficiency of such systems for drugs. The diminished 
efficacy of the administered dose due to incomplete drug 
release from the DDS caused by the relatively short gastric 
residence time in humans (2–3 h) through the major 
absorption zone such as proximal part of GIT. Thus, 
considerations have led to the development of oral 
controlled-release(CR) dosage forms possessing gastric 
retention capabilities are the control of location of a Drug 
delivery system, especially for drugs exhibiting an 
absorption window in the GI tract or drugs with a stability 
problem, in a specific region of the GI tract offers several 
advantages.[3] In this review the technological developments 
which are currently invented in floating drug delivery system 
and patented or clinically available products are also 
discussed.   
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PHYSIOLOGY OF GASTROINTESTINAL TRACT 
 
Figure 1: Anatomy of stomach 
The stomach motility is distinct in 2 states. During fasting 
state, inter digestive series of electrical events takes place, 
which cycles both through stomach and intestine every 2 to 3 
hours. This is called the interdigestive myoelectric cycle or 
migrating myloelectric cycle (MMC), as described by Wilson 
and Washington (1989) it is further divided into following 4 
phases. 
1. Phase I (basal phase) with contractions upto 40 to 60 
minutes. 
2. Phase II (pre burst phase) with intermittent action 
potential and contractions it lasts for 40 to 60 minutes and 
the intensity and frequency also increases gradually during 
the phase progresses.  
3. Phase III (burst phase) It includes intense and regular 
contractions for short period and stays upto 4 to 6 minutes. 
It is also known as the house keeper wave because this wave 
do all the undigested material is swept out of the stomach 
down to the small intestine.  
4. Phase IV It is occurs between phases III and I of 2 
consecutive cycles and last for 0 to 5 minutes. The pattern of 
contractions changes from fasted to that of fed state after 
taking mixed meal. This is also called as digestive motility 
pattern and bring out continuous contractions as in phase II 
of fasted state. These contractions reduces the size of food 
particles less than 1mm, which are pushed toward the 
pylorus in a suspension form. During the fed state onset of 
migrating myloelectric cycle is delayed resulting in reduced 
gastric emptying rate.[4] 
 
  
Figure 2: Schematic representation of myloelectric cycle 
Needs for gastric retention 
1) Drugs which are absorbed from the Upper part of the 
gastrointestinal tract (GIT).  
2) Drugs which are less soluble in GIT or are degrades by the 
basic pH they administered at the Lower (distal) part of GIT.   
3) Drugs which are absorbed during the variable gastric 
emptying time. To treat certain conditions Local or sustained 
drug delivery to the stomach and small intestine.   
4) Mostly very useful for the treatment of peptic ulcers 
caused by Helicobacter Pylori Infections.[2] 
FLOATING DRUG DELIVERY SYSTEMS (FDDS):  
These formulations have very low density and so float over 
the gastric materials.  
1. Bioadhesive systems: They are fix with stomach mucosa 
and hence, gives the localized retention of the system.  
2. Swelling systems: These systems absorb water and get 
enlarged size by swelling.   
3. High density systems: These are stays in the stomach for 
longer period of time, by settling down to the folds of 
stomach.[2][4] 
Floating systems are low density systems that have 
maximum buoyancy to float on the gastric material and 
remain in the stomach for longer period of time. During the 
system hang over the gastric contents, the drug is released 
sustainly with desired rate, which results in elevated gastric 
retention time and minimizes fluctuation also. A  minimum 
stomachic content required to allow the proper achievement 
of the buoyancy retention principle, a minimum floating 
force (F) is also required to keep the dosage form to be 
buoyant on the Surface of the gastric content. A novel 
apparatus for determination of resultant weight has been 
reported to measure the kinetics of floating force. The 
apparatus works by measuring the force equivalent to F (as a 
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function of time) that is required to maintain the submerged 
dosage form. The drug floats efficiently if force F is on the 
higher positive.  
F = F (buoyancy) – F (gravity) 
= (DF – Ds) g.v----------------- (1) 
Where, F= total vertical force,  
DF = fluid density, 
Ds= object density,                                                                        
v= volume and g = acceleration due to gravity. 
 
These are oral dosage forms (capsule or tablet) that are 
designed to prolong the retention time of the drug within the 
GI tract . The recent literature survey shows that interest 
increased in academics and industrial research regarding the 
development of novel dosage forms that can be sustained in 
the stomach for a longer and predictable period of time. The 
numerous marketed FDDS are given in table 1.[7] 
 
 
CLASSIFICATION OF FDDS 
(A) Effervescent FDDS 
        1. Gas generating system  
        2. Volatile liquid containing system 
(B) Non- Effervescent FDDS 
 1. Colloidal gel barrier system 
 2. Microporous compartment system 
 3.  Floating microsphere 
 4. Alginate floating beads. 
(C) Raft forming system 
 
FACTORS AFFECTING THE GASTRIC EMPTYING 
1. Density 
2.  size   
3. shape of the dosage form 
4. Simultaneous intake of the food and its nature, caloric 
content and frequency of intake 
5.  Biological factor such as gender, posture, age, sleep, 
physical activity, body weight, and disease states (e.g. 
B.P, diabetes).[6] 
a) Effervescent floating dosage forms 
These systems are matrix types which are prepared  by using 
various effervescent compounds like Sodium carbonate, 
Calcium carbonate, Tartaric acid and Citric acid and 
swellable like HPMC, methyl cellulose and chitosan based 
polymers . These dosage forms are formulated in such a way 
that when it comes in contact with the acidic gastric 
contents, CO2 liberation takes place and this gas entrapped in 
to the swollen hydrocolloids network which gives buoyancy 
to the dosage forms such as Amlodipine besylate which is 
shown in figure no 3 (a).  
 
 
Figure 3: (a) Effervescent Systems (b) Swelling Floating 
System 
 
b) Non effervescent floating dosage form 
These dosage forms made from gel forming or swellable 
hydrocolloids (cellulose type), polysaccharides and polymers 
which forms matrix like polymethacrylate, polycarbonates 
and polystyrene. The formulation is made by mixing the drug 
and the gel-forming polymers, after administration by orally 
of this dosage form get swells during in contact with gastric 
content. The buoyancy of solid dosage form was achieved 
due to the air entrapment in to the swollen gel like structure 
acts as a reservoir and allows slowly release of drug through 
the polymer mass which is shown in figure no. 3 (b).[5] 
METHODS OF PREPARATION  
1) Solvent evaporation method   
For to create hollow inner core the floating multi-particulate 
dosage form was prepared by solvent diffusion and 
evaporation methods. The polymer was dissolved in an 
organic solvent and then drug is dissolved in prepared  
polymer organic solution. Then drug solution is emulsified 
after into an aqueous phase which containing PVA (Polyvinyl 
alcohol) to form O/W emulsion, After that the organic 
solvent is evaporated by increasing the temperature or by 
continuous stirring. The solvent elimination leads to 
precipitation of polymer at the oil in water ( O/W) interface 
of droplets, by the formation of cavity and thus made them 
hollow to introduce the floating properties. The polymers 
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considered for the development of such floating systems 
include Cellulose acetate, Chitosan, Polyvinyl acetate, 
Acrycoat, Methocil, Eudragit, Polyacrylates, Carbopol, 
Polycarbonates, Polyethylene oxide and Agar. Floating 
microparticles consisting of Polypropylene foam powder, 
Theophylline (as the model drug) and Eudragit RS, ethyl 
cellulose or polymethylmethacrylate (PMMA) were prepared 
with an O/W solvent evaporation method (Figure no. 4a). 
The rate-controlling polymer and drug were dissolved in 
Methylene chloride. After that polypropylene powder was 
then dispersed within prepared organic phase. The final 
suspension was further emulsified into an another aqueous 
PVA (polyvinyl alcohol) solution. The macroparticles were 
separated by sieving method and give washing with cold 
water and dried them in a desiccator with sufficient amount 
of silica gel; they are all irregular in shape and size with 
highly porous structure. Majorly, the drug combining 
efficiency was high and almost independent of the 
theoretical assumption of drug loading in the system. A 
broad spectrum of drug release patterns can be obtained 
with the evaluation of formulations. Major benefit of the such 
novel preparation technique include short preparation time, 
no exposure of the component to high temperatures, the 
tendency to avoid toxic organic solvents and high drug 
combining efficacy (near to 100%). Floating microparticle 
system consisting of polymer foam powder, model drug (e.g. 
Chlorpheniramine maleate) and a secondary polymer 
[Polymethyl methacrylate)] were prepared by soaking 
microporous foam particles with an organic solution 
containing drug and polymer (Figure 4b). Additionally, the 
low- density microparticles can be compressed into fastly 
disintegrating tablets, providing an easily administrable oral 
dosage form.   
 
Figure 4: Schematic presentation of the preparation of 
floating microparticles based on low-density foam powder, 
using (a) The solvent evaporation method or (b) The soaking 
method. 
 
2) Ionotropic gelation method  
The mechanism of Ionotropic gelation is depend on the 
ability of polyelectrolytes to cross link with presence of 
counter ions leads to formation of beads. Since, the use of 
Alginates, Chitosan, CMC and Gellan gum for the 
encapsulation of drugs this gelation technique has been 
widely used for preparation of the beads. These anions forms 
mesh like structure by combining with the polyvalent cations 
and insert gelation by combining mainly to the anion blocks. 
The hydrogel beads are prepared by dropping a drug-loaded 
polymer solution into the polyvalent cationic aqueous 
solution. The introduction of biomolecules can also be 
possible into these beads under mild conditions to maintain 
their 3D structure. The schematic representation of 
ionotropic gelation method is shown in figure 5.[6] 
 
Figure 5: Ionotropic gelation method 
3) Emulsion solvent diffusion method  
Microballoons (hollow microspheres) with drug in their 
outer polymer shell prepared by novel emulsion solvent 
diffusion method. The preparation procedure and 
mechanism of microballoon formation is schematically 
illustrated in Figure no. 6. A solution of polymer and drug in 
ethanol methylene chloride is poured into an agitated 
aqueous solution of poly (vinyl alcohol). The subsequent 
evaporation of the entrapped methylene chloride leads to the 
formation of internal cavities within the microparticles.[6]   
 
Figure 6: Preparation technique (emulsion-solvent diffusion 
method) and   mechanism of ‘microballoon’ formation. 
 
EVALUATION OF FLOATING DRUG DELIVERY 
SYSTEMS [8] 
1. Angle of Repose:  Angle of repose used to calculate 
powder flowability by assessing interparticular friction. If 
angle of repose is higher than poor is the flowability of 
powder. Determination of  angle of repose of each powder 
blend was performed by glass funnel method, using 
following equation, 
 
Where, θ- angle of repose,  
h - height of pile above the flat surface, 
r - radius of the circle formed by the powder blend.    
2. Bulk Density: It is ratio of mass of microsphere to bulk 
volume of microsphere. Bulk density pf powder may vary 
Baviskar et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):839-846 
ISSN: 2250-1177                                                                                  [843]                                                                                      CODEN (USA): JDDTAO 
dissolution and other properties and depends on the particle 
size, shape and affinity of particles to adhere together one. 
The bulk density of beads was calculated by following 
equation,  
 
 
3. Tapped density: Tapped density used to determine 
flowability and packing geometry of formulation. Tapped 
density is the ratio of weighed amount of sample and volume 
of powder determined by tapping using measuring cylinder. 
Tapped density of formulated beads was calculated by 
following equation, 
 
4. Carr’s compressibility index: This is an very important 
property in maintaining uniform weight of dosage form. It is 
calculated using following Equation, 
 
 
5. Hausner’s ratio: It is the ratio of  tapped density and bulk 
density. Hausner’s ratio less than 1.25 shows good flow and 
greater than 1.5 shows poor flow property whereas between 
1.25 and 1.5 indicates intermediate glidant flow. Hausner’s 
ratio can be calculated by formula, 
 
6. Morphology study: For characterization of surface of 
prepared beads Scanning Electron Microscopy (SEM) was 
performed. Beads are mounted directly onto the sample pan 
and coated with gold ion to analyze it for surface 
morphology. 
7. Particle size analysis: The particle sizes of formulated 
beads were measured by an optical microscope fitted with 
calibrated eyepiece and stage micrometer along with particle 
size distribution was calculated. 
8. Determination of Percentage yield: The formulated 
beads were collected and weighed. The measured weight 
was divided by the total amount of all ingredients, which 
were used for the formulation of the beads. 
 
9. Drug Entrapment Efficiency: Beads containing 100 mg 
equivalent of the drug were taken for evaluation purposes. 
The amount of drug entrapped was calculated by extracting 
crushed beads with aliquots of 0.1N HCl repeatedly. The 
resultant extract was transferred to a 100 ml volumetric 
flask and the final volume was made up to 100ml using 0.1N 
HCl. The solution was then filtered and the absorbance was 
measured at λmax wavelength against appropriate blank. The 
amount of drug entrapped in the beads was calculated by the 
following formula, 
 
10. In vitro buoyancy study:   Beads (300mg) were put 
over the surface of a USP dissolution apparatus type II filled 
with 900 ml of 0.1 N HCl containing 0.02% Tween 80 
solution. The solution was stirred with a paddle rotating at 
100 rpm for 12 hr. The floating and the settled part of beads 
were recovered separately and they were dried and weighed 
separately. Buoyancy percentage was calculated as the ratio 
of the mass of the floating beads and the total mass of the 
beads. 
 
Where, 
Qf =Weight of floating beads 
Qs =Weight of settled beads 
11. In-vitro drug release study: The drug release study 
from formulated beads is performed with the help of USP 
dissolution apparatus Type I in 900 ml of 0.1 N HCl 
dissolution media (pH- 1.2) at 100 rpm and 37°C 
temperature. 2 ml sample was withdrawn at every1 hr. time 
interval for 12 hr and same volume of fresh solution was 
replaced to maintained sink condition. Withdrawn samples 
were assayed spectrophotometrically at suitable wavelength. 
The drug release by beads was analyzed by UV spectro- 
photometer. 
 12. Determination of Moisture Content: Moisture content 
study was performed by using an IR moisture balance by 
placing the beads at 60 °C for 10 min.  
14. Drug-excipient interaction It is measured by using 
FTIR and HPLC. Appearance of a new peak and/or 
disappearance of original drug peaks or excipient peaks 
indicate the drug excipient interaction.  
15. Floating lag time:  It is the time taken to float tablet onto 
the surface of medium after it is kept in to the dissolution 
medium. It is measured in minutes or seconds.  
16. In vivo evaluation of gastric retention:  The position of 
the dosage form in the GIT is analyze by  an imaging 
technique such as γ-scintigraphy and X-ray. In γ-
scintigraphy, a small amount of stable isotope is mixed in the 
dosage forms during its preparation. The radiation of a γ- 
emitting radio-nuclide in a formulation allows indirect 
external observation using a γ-camera or scinti scanner. For 
x-ray analysis, barium sulphate is used as a contrast medium. 
It helps to locate dosage form in the Gastrointestinal tract by 
which prediction and correlation of the gastric emptying 
time and the passage of dosage form can be done.  In 
addition, gastro-endoscopy and ultrasonography studies can 
be included in the in vivo evaluation of gastric retention 
systems. Gastroscopy comprises of per-oral endoscopy, used 
with ocular and video systems. Ultrasonography is not 
routinely used in the evaluation of such systems. In vivo 
plasma profiling of drug can also be obtained by performing 
the study in suitable animal model. [3] 
17. Water uptake study:  It is performed by introduction 
the dosage form in simulated gastric fluid at 37oC and study 
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the dimensional changes, such as diameter and thickness, at 
regular interval of time. The swollen beads are weighed and 
water uptake is calculated in the terms of percentage weight 
gain, as given:   
                                        Wu= (Wt.-Wo) x 100 
                                                            Wo 
Where,  Wt and Wo are the weight of the tablet after time t 
and initially, respectively 
Advantages of Floating Drug Delivery:  
1. Enhancement bioavailability of drug: The bio- 
availability of some drugs for e.g. Levodopa      In 
controlled release –gastric retention drug delivery is 
significantly increases in comparison to administration 
of non-gastric retentive polymeric formulations. 
2. Enhancement First-Pass hepatic biotransformation: 
When the drug is presented to the metabolic enzymes 
(cytochrome P-450, in particular CYP-3A4) in a 
controlled manner, the pre- systemic metabolism of the 
drug may be considerably increased rather than by a 
bolus input.  
3. Sustained delivery of drug dosing:  
4. Targeted drug therapy for local ailments in the 
proximal GI tract: The prolonged and sustained 
administration of the drug from floating system to the 
stomach may be useful for local therapy in the stomach. 
[2]  
5. Reduced variation in plasma drug concentration: The 
fluctuations in plasma drug concentration are reduces, 
and concentration-dependent adverse effects that are 
comes with peak concentrations    can also be 
minimizes 
6. Reduced counter-activity of human body: Slow release 
of the drug into the body reduces the counter activity 
caused due to higher drug efficiency.  
7. Extended time over effective concentration: The 
sustained mode of administration enables prolongation 
of the time   
8. Improvement in Receptor activation selectivity: FDDS 
decreases the drug concentration variation over a 
critical concentration and thus increases the 
pharmacological effects.[7]  
9. Reduced adverse activity at the intestine: Retention of 
the drug in gastric retentive formulation at stomach, 
minimizes the amount of drugs that reaches the colon 
and hence prevents the degradation of drug that may 
degraded in the colon.  
10. Site specific Delivery of drug 
11. Gastro retentive drug delivery can produces prolong 
and sustain release of drugs from dosage forms which 
provide local therapy in the GIT. 
12. The controlled, slow delivery of drug form 
gastroretentive dosage form provides sufficient local 
action at the diseased site, thus minimizing or 
eliminating systemic exposure of drugs. 
13. This site specific drug delivery decreases side effects of 
drug.  
14. Gastroretentive dosage forms minimize the fluctuation 
of drug concentrations and side effects. Therefore, 
concentration dependent side effects that are related 
with maximum concentrations can be prevented.  
15. Gastroretentive drug delivery can minimize the counter 
activity of the body leading to higher drug efficiency.  
16. Reduction of fluctuation in drug concentration makes it 
possible to obtain improved selectivity in receptor 
activation.  
17. The sustained mode of drug release from 
Gastroretentive doses form enables extension of the 
time over a critical concentration. [11] 
APPLICATIONS  
Floating multiparticulate drug delivery gives several 
applications for drugs having poor bioavailability because of 
the narrow absorption window in the upper part of the GI 
tract. It retains the dosage form at the site of absorption and 
thus increases the bioavailability of drug. These are 
summarized as follows.  
1) Sustained drug delivery  
Hollow microspheres of NSAID are very effective for 
controlled release as well as it reduces the major side effect 
of gastric irritation; e.g. floating microspheres of 
Indomethacin are more beneficial for rheumatic patients.  
2) Site-specific drug delivery  
These systems are particularly useful for drugs that are 
specifically absorbed from stomach or the proximal part of 
the small intestine. Bilayer-floating capsule was developed 
for local delivery of Misoprostol, which is a synthesized from 
prostaglandin E1 and as a gastric ulcers protective caused by 
administration of NSAIDs. 
3) Absorption enhancement  
Drugs which have poor bioavailability because of site- 
specific absorption from the proximal part of the GI tract are 
potentially strong candidates to be formulated as floating 
drug delivery systems, thereby maximizing their 
absorption.[11] 
INNOVATIVE TECHNOLOGIES FOR FDDS 
1. Oleotec™ and Soctec™ : Oleotec™ and Soctec™ gastro-
retentive capsule technology are innovated by 
Skyepharma company. For Drugs having high 
therapeutic doses, Oleotac TM  technique is designed 
but it is not suitable for the conventional dosage form. 
Drugs that show effect primarily in the proximal part of 
the gastro intestinal tract are developed by this 
technique. Oleotec system is basically a gel 
incorporated in the form of stick pack that forms a 
continuous layer at walls of the stomach. Soctec TM  
system is designed for the drugs that should be 
administered as controlled release and should be 
absorbed in the proximal part of intestine for 
increasing the bioavailability of drug. Soctec is an 
elongated capsule fill with drug. It can be used with a 
range of drugs that have a short absorption window 
and are preferably absorbed in the proximal intestine 
fragment. It can also improve the bioavailability of 
drugs that are degraded by the basic pH of the distal 
part of GIT.  
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Figure 7: SoctecTM Gastro retentive capsule 
2. Accordion Pill™ Technology: This is a versatile gastro 
adhesive formulation composed of the biodegradable 
polymers. It is a multi-layer, planar structure, folded to 
an accordion shape into regular standard size capsule. 
When capsule reaches to the stomach, it dissolves, the 
folded pill unfolds and is sustained in the stomach last 
up to 12 hours. During it is in the stomach, the pill 
releases the drug in a controlled manner towards the 
proximal part of the GI tract which gives prolonged and 
continuous absorption phase of the drug in the upper 
part of the GI tract, resulting in increased efficacy and 
safety profiling, as well as reducing frequency dosing. 
The drug release mechanism is not dependent on the 
Accordion pill™ retention mechanism. After the 
Accordion Pill™ is expelled from the stomach, it is get 
degraded in the intestinal media. Drugs which are 
belonging to the BCS Class II and BCS Class IV are more 
preferable for this system. 
 
Figure 8:    Accordion Pill™ Technology 
3. Gastro Retentive Innovative Device (GRID): Gastro 
Retentive Innovative Device (GRID) is an ideal once-a-
day system for drugs that are otherwise absorbed only 
in stomach or small intestine. GRID is designed so that 
drug is retained in the stomach for over an eight-hour 
span. Longer retention in stomach improves the drug 
absorption. The tablet offers a combination of instant 
and sustained drug release profiles, and being once a 
day improves patient compliance. This innovative 
system is a dosage form with specialized multiple 
coatings. On ingestion of the dosage form along with 
food, it floats instantaneously on the gastric contents. 
GRID's coatings are activated by gastrointestinal fluid, 
eventually leading to swelling, to about eight to eleven 
times its initial volume. Plasma concentrations for 
medicines are thus maintained in the therapeutic range 
for a prolonged period; hence this dosage form can be 
used as a "Once-a- day" system. Specific release profiles 
for drugs can be tailored to achieve combination of 
immediate and slow release using this innovative 
dosage form. Retention of the dosage form close to its 
site of absorption may help in reducing the dose and 
thus the side effects.  
 
Figure 9: Gastro Retentive Innovative Device 
4. Multiple Polymers Hydrophilic Matrix Technology: 
Multiple polymer hydrophilic matrix technology is a 
sustained gastro drug delivery system.  Cetapin XR is a 
formulation of this system patented by Sanofi which 
contain Metformin XR as a drug , to achieve extended 
release of Metformin hydrochloride. The polymers are 
made by combining non-ionic and ionic hydrophilic 
polymers. The drug release from the matrix pore 
occurs through a process of dissolution of the drug and 
undergoing diffusion through the gel matrix in a 
sustained manner. This technology gives consistent and 
reproducible results with good optimal absorption, 
minimum irritation, increased plasma drug levels and 
good bioavailability.  
 
Figure 10: Hydrophilic Matrix Technology 
5. Acuform® technology: Acuform® is formulated 
patented by Depomed’s. it is a polymer-based 
technology formulated to optimize drug delivery in GIT. 
This technology permit targeted and controlled 
delivery of drug to the proximal (upper) GIT which is 
the preferable absorption site for many oral drugs. In 
particular, for drugs that are absorbed in the upper GI 
region this technology is an effective delivery solution. 
It is also valuable for drugs insoluble in water, irritating 
for mucosa of the small intestines or not safe in the 
distal GIT region and it is more effective when plasma 
drug levels have less fluctuation.  
6. Gastrointestinal Permeation Enhancement 
Technology: Gastrointestinal  Permeation 
Enhancement Technology (GIPET) is developed by 
Merrion Pharmaceutical’s and it is unique approach 
which allows drugs that now can only be injected by 
parenterally (injectable). For to converted into oral 
solid forms e.g. tablet/capsule, as well as enhance the 
absorption of oral drugs. Gastrointestinal Permeation 
Enhancement Technology uses selectively formulated 
oral formulations absorption enhancers which activate 
micelle formation undergoing transport of drug and 
increasing absorption with good reproducibility and a 
strong safety profile.   
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Figure 11:  Gastrointestinal Permeation Enhancement Technology 
7. Micropump Technology:  Flamel’s Micropump® 
platform felicitate either sustained, or both delayed and 
sustained, delivery of small molecule drugs through oral 
route. Micropump consists of a multiple-particulate 
system which having 5,000 to 10,000 microparticles per 
capsule or tablet. The microparticles having 200-500 
microns diameter size  release the drug at an adjustable 
rate and over an prolonged period of time. Micropump’s 
key includes extended release in the Gastrointestinal 
tract allowing mean plasma retention times to be 
prolonged for up to 24 hours. 
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